Chronic hepatitis delta virus-infected patients being treated with pegylated interferon-alfa therapy may experience a change in natural killer cell subsets, according to data from a recent study.
Researchers conducted an analysis of natural killer (NK) cells in 31 chronically hepatitis delta virus (HDV)-infected patients before and during treatment with interferon-alfa-2a (IFN-a), then compared the results with 15 patients with hepatitis B virus (HBV) mono-infection and 49 healthy controls. To measure IFN-a responsiveness associated with NK cell differentiation, 20 healthy donors — 10 with immature and 10 with terminal NK cell phenotypes — were used. Researchers used multicolor flow cytometry to identify major NK cell subsets in peripheral blood mononuclear cells (PBMCs) from all patients. Full Story »